Market Overview

Don't Call The Trade War A Trade War, Says JPMorgan Chase CEO Jamie Dimon

Share:
Don't Call The Trade War A Trade War, Says JPMorgan Chase CEO Jamie Dimon
Related JPM
Taking A Trade Break: Weak Overseas Data Center Stage Despite Solid Retail Sales
Bristol-Myers, Costco, JPMorgan And XLU: 'Fast Money' Picks For December 14
Identifying the Next Big Trend Is Not Enough to Win (GuruFocus)

President Donald Trump's trade war against China is being mislabeled as the two countries are merely engaged in a "trade skirmish," according to JPMorgan Chase & Co. (NYSE: JPM) CEO Jamie Dimon.

What Happened

A simple explanation exists for why the stock market is shrugging off Trump's trade war with China, Dimon told CNBC in an interview. The reality is the two countries aren't at war, and even under a worst-case scenario, the financial impact to consumers from Trump's new tariffs are minuscule when compared to the $20-million American GDP.

Why It's Important

The White House is right to raise trade concerns with China, although Dimon said he would have taken a different approach in doing so, as tariffs create uncertainty and risks erasing some of the positive benefits from tax and regulatory reform and other pro-business policies, he said. 

What's Next

The "trade tit-for-tat" could expand into a full-blown trade war and involve more countries, Dimon — but China and the U.S. can find a resolution and put an end to the dispute. The bank executive said he "doesn't know" which scenario is more likely.

"We could raise tariffs more, we could add tariffs to more things, the Chinese can retaliate in other ways — and I don't think that's good, but it's not a devastating thing," Dimon concluded.

Related Links:

US, China Announce New Tariffs: Wall Street Reacts

Life During Wartime: Ag Futures Start A Fresh Crop Year Under Tariffs

Screenshot courtesy of CNBC. 

Posted-In: China Donald Trump Jamie Dimon tariffsPolitics Media General Best of Benzinga

 

Related Articles (JPM)

View Comments and Join the Discussion!

Merck Or Pfizer: Which Is The Better Large-Cap Pharma Stock?

Northrop Grumman's Unit Wins $22M Navy Deal To Modernize AARGM